In recent decades, the concept of "modifiable" cardiovascular risk factors has evolved dramatically, thanks to advancements in our understanding of pathophysiology and disease progression, paired with breakthroughs in pharmacologic therapy. This video explores the latest developments in cardiovascular treatments and the expanding definition of modifiable risk factors.
Join us as we dive into the significant milestones achieved in 2023 and early 2024. Notably, the FDA approved colchicine 0.5 mg (Lodoco) tablets in June 2023 as the first anti-inflammatory atheroprotective cardiovascular treatment. This landmark approval aims to reduce the risk of myocardial infarction, stroke, coronary revascularization, and cardiovascular death in patients with established atherosclerotic disease or multiple risk factors for cardiovascular disease.
The progress continued into 2024, with two more groundbreaking FDA approvals:
March 08, 2024: Semaglutide 2.4 mg (Wegovy) was approved as the first treatment for reducing cardiovascular risk in patients with overweight or obesity.
March 22, 2024: Bempedoic acid (Nexletol) and its combination with ezetimibe (Nexlizet) received label expansions for primary and secondary prevention of cardiovascular risk, marking the first LDL-C-lowering non-statin agent to gain a primary prevention indication.
Looking ahead, lipoprotein(a) [Lp(a)] has emerged as a crucial prognostic factor for cardiovascular risk. Innovative agents like olpasiran, pelacarsen, and SLN360 show promise in reducing Lp(a) levels, potentially adding another powerful tool in cardiovascular disease prevention.
In this insightful interview, Dr. Payal Kohli, associate clinical professor of Medicine at the University of Colorado Anschutz and medical director of Cherry Creek Heart, provides an in-depth look at these advancements and discusses their implications for healthcare. Dr. Kohli also emphasizes the vital role primary care and internal medicine practitioners play in adopting these new treatments and integrating the latest pathophysiological insights into patient care.
🔔 Subscribe to our channel for more updates on the latest in cardiovascular treatments and risk factor management!
📢 Don't forget to like, comment, and share this video with your colleagues!
www.hcplive.com/view/changing...
#CardiovascularHealth #HeartDisease #MedicalAdvancements #FDAApproval #Cardiology #Healthcare #PrimaryCare #InternalMedicine #CardiovascularRisk #ModifiableRiskFactors